Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes

Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo

(2015) Cara Lunn Shirai et al.   CANCER CELL

Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

(2014) Guillermo Garcia-Manero   AMERICAN JOURNAL OF HEMATOLOGY

Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes

(2014) Raphael Itzykson et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome

(2014) T-C Chen et al.   Blood Cancer Journal

Functional and cancer genomics of ASXL family members

(2013) M Katoh   BRITISH JOURNAL OF CANCER

Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact

(2013) Ulrike Bacher et al.   BRITISH JOURNAL OF HAEMATOLOGY

Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations

(2013) Daichi Inoue et al.   JOURNAL OF CLINICAL INVESTIGATION

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

(2013) T Haferlach et al.   LEUKEMIA

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

(2012) F. Thol et al.   BLOOD

The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution

(2012) S.-J. Wu et al.   BLOOD

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

(2012) Véronique Gelsi-Boyer et al.   Journal of Hematology & Oncology

Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts

(2012) Rui Cui et al.   LEUKEMIA RESEARCH

TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes

(2012) Jieyu Wang et al.   LEUKEMIA RESEARCH

SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value

(2011) M. M. Patnaik et al.   BLOOD

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

(2011) L. Malcovati et al.   BLOOD

Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes

(2011) Felicitas Thol et al.   JOURNAL OF CLINICAL ONCOLOGY

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

(2011) F Damm et al.   LEUKEMIA

Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

(2011) Timothy A Graubert et al.   NATURE GENETICS

SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts

(2011) E. Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

(2010) Gorica Nikoloski et al.   NATURE GENETICS

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Mutations of polycomb-associated geneASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia

(2009) Véronique Gelsi-Boyer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group

(2009) Christoph E. Heilig et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE